Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07104331 · ClinicalTrials.gov registry record · Phase 2
SARC046: A Phase II Trial of Nab-Sirolimus in Patients With Progressing or Symptomatic Epithelioid Hemangioendothelioma
A Phase 2 study of Epithelioid Hemangioendothelioma (EHE), sponsored by Sarcoma Alliance for Research through Collaboration.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 41
- Enrollment target
- 6
- Study locations
NCT07104331: Recruiting Phase 2 study of Epithelioid Hemangioendothelioma (EHE), sponsored by Sarcoma Alliance for Research through Collaboration.
NCT07104331 is a Phase 2 study of Epithelioid Hemangioendothelioma (EHE) that is actively recruiting participants, run by Sarcoma Alliance for Research through Collaboration. The registered enrollment target is 41 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (69% lower). The trial reports 6 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07104331, a Phase 2 study of Epithelioid Hemangioendothelioma (EHE), is actively recruiting participants, sponsored by Sarcoma Alliance for Research through Collaboration.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 41 participants
- Enrollment target
- 6
- Study locations
Study Summary
This is a non-randomized, open label, single arm Phase II trial with a two-stage design with histologically-confirmed metastatic and/or recurrent epithelioid hemangioendothelioma requiring systemic treatment. nab-Sirolimus 100 mg/m2 will be administered as an intravenous infusion over 30 minutes on Days 1 and 8 of each 21-day cycle. The primary objective is to determine ORR by RECIST v1.1 of nab-sirolimus in patients with EHE who require systemic treatment.
Primary Outcome
To determine ORR by RECIST v1.1 of nab-sirolimus in patients with EHE who require systemic treatment.
Conditions Studied
Interventions
- DRUG nab-Sirolimus
Study Locations (6)
Massachusetts
- Brigham and Women's Hospital - Boston
- Dana-Farber Cancer Institute - Boston
California
- Stanford University - Stanford
Colorado
- University of Colorado - Aurora
Missouri
- Washington University St. Louis - St Louis
New York
- Sloan Kettering Institute for Cancer Research - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2026-02-24 |
| Est. Completion | 2029-08-30 |
| Phase | Phase 2 |
What NCT07104331 shows while recruiting
NCT07104331 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 41 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (69% lower).
The record links to 1 condition, with Epithelioid Hemangioendothelioma (EHE) appearing as the primary indexed condition, and to 1 intervention - of which nab-Sirolimus is the first listed.
NCT07104331 lists 6 locations in 5 states (Massachusetts, California, Colorado).
Frequently Asked Questions
What is clinical trial NCT07104331 about?
NCT07104331 is a clinical study titled "SARC046: A Phase II Trial of Nab-Sirolimus in Patients With Progressing or Symptomatic Epithelioid Hemangioendothelioma". This is a non-randomized, open label, single arm Phase II trial with a two-stage design with histologically-confirmed metastatic and/or recurrent epithelioid hemangioendothelioma requiring systemic treatment. nab-Sirolimus 100 mg/m2 will be administered as an intravenous infusion over 30 minutes on ...
What is the current status of trial NCT07104331?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2026-02-24. Estimated completion is 2029-08-30.
What conditions does trial NCT07104331 study?
This clinical trial studies the following conditions: Epithelioid Hemangioendothelioma (EHE).
What interventions are being tested in trial NCT07104331?
The interventions under investigation include: nab-Sirolimus (DRUG).
Who is sponsoring clinical trial NCT07104331?
This trial is sponsored by Sarcoma Alliance for Research through Collaboration, which has 20 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07104331 being conducted?
This trial has 6 study locations across California, Colorado, Massachusetts, Missouri, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Epithelioid Hemangioendothelioma (EHE)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07104331's enrollment target sits among peer trials
41 1352nd of 2000 higher than 640 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03449238 · 41 participants · Phase 1
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
- NCT03900793 · 41 participants · Phase 1
Losartan + Sunitinib in Treatment of Osteosarcoma
- NCT04082520 · 41 participants · Phase 2
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
- NCT04220190 · 41 participants · Phase 2
RAPA-501 Therapy for ALS
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI